Παρακαλώ χρησιμοποιήστε αυτό το αναγνωριστικό για να παραπέμψετε ή να δημιουργήσετε σύνδεσμο προς αυτό το τεκμήριο:
https://hdl.handle.net/123456789/1107| Τύπος: | Άρθρο σε επιστημονικό περιοδικό |
| Τίτλος: | GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: a systematic review and meta-analysis |
| Συγγραφέας: | [EL] Καραγιάννης, Θωμάς[EN] Karagiannis, Thomas [EL] Τσάπας, Απόστολος[EN] Tsapas, Apostolos [EL] Αθανασιάδου, Ελένη[EN] Athanasiadou, Eleni [EL] Αυγερινός, Ιωάννης[EN] Avgerinos, Ioannis [EL] Λιάκος, Άρης[EN] Liakos, Aris [EN] Matthews, David [EL] Μπεκιάρη, Ελένη[EN] Bekiari, Eleni |
| Ημερομηνία: | 08/03/2021 |
| Περίληψη: | Aims: To assess the cardiovascular effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose co-transporter-2 (SGLT2) inhibitors in older people with type 2 diabetes. Methods: PubMed, Embase, and Cochrane library were searched up to November 2020 for cardiovascular outcomes trials with GLP-1 RAs or SGLT2 inhibitors that reported results for older patients with type 2 diabetes. Random-effects meta-analyses were conducted for different age subgroup categories. Results: A total of 11 studies (93,502 patients) were included. Consistent with their effect in the overall population, in patients 65 years, GLP-1 RAs reduced major adverse cardiovascular events (MACE) (hazard ratio [HR], 0.86; 95% confidence interval [CI], 0.80–0.92), cardiovascular death, stroke, and myocardial infarction. In the same age subgroup, SGLT2 inhibitors reduced MACE (HR, 0.90; 95% CI, 0.83–0.98) but had a neutral effect on its components. They also reduced heart failure hospitalization (HR, 0.62; 95% CI, 0.51–0.76), an effect that was not evident in patients <65 years, and the composite renal endpoint (HR, 0.57; 95% CI, 0.43–0.77). Meta-analyses for patients 75 years yielded similar results. Conclusions: In older adults with diabetes, GLP-1 RAs reduced MACE and its components. SGLT2 inhibitors reduced MACE, and heart failure and renal outcomes. |
| Γλώσσα: | Αγγλικά |
| Σελίδες: | 10 |
| DOI: | 10.1016/j.diabres.2021.108737 |
| EISSN: | 1872-8227 |
| Θεματική κατηγορία: | [EL] Ιατρική έρευνα και Πειραματική ιατρική[EN] Research and Experimental medicine |
| Λέξεις-κλειδιά: | type 2 diabetes; older adults; cardiovascular outcomes; heart failure; renal outcomes; meta-analysis |
| Κάτοχος πνευματικών δικαιωμάτων: | © 2021 Elsevier B.V. All rights reserved. |
| Ηλεκτρονική διεύθυνση του τεκμηρίου στον εκδότη: | https://www.sciencedirect.com/science/article/pii/S0168822721000905 |
| Ηλεκτρονική διεύθυνση περιοδικού: | https://www.sciencedirect.com/journal/diabetes-research-and-clinical-practice |
| Τίτλος πηγής δημοσίευσης: | Diabetes Research and Clinical Practice |
| Τόμος: | 174 |
| Σελίδες τεκμηρίου (στην πηγή): | Article no 108737 |
| Σημειώσεις: | This research was funded by Greece and the European Union (European Social Fund- ESF) through the Operational Programme «Human Resources Development, Education and Lifelong Learning 2014-2020» in the context of the project “Methodological framework for the development and updating of individualized and evidence-based guidelines. A case study on type 2 diabetes mellitus (MIS 5047909)”. |
| Εμφανίζεται στις συλλογές: | Ερευνητικές ομάδες |
Αρχεία σε αυτό το τεκμήριο:
Το πλήρες κείμενο αυτού του τεκμηρίου δεν διατίθεται προς το παρόν από το αποθετήριο